About La Jolla Pharmaceutical
La Jolla Pharmaceutical is a company based in San Diego (United States) founded in 1989 was acquired by Innoviva in July 2022. The company has 71 employees. La Jolla Pharmaceutical has completed 1 acquisition, including Tetraphase Pharmaceuticals. La Jolla Pharmaceutical offers products and services including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN. La Jolla Pharmaceutical operates in a competitive market with competitors including Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others.
- Headquarter San Diego, United States
- Employees 71
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website lajollapharmaceutical.com
- Social LinkedIn X
- Acquired by Innoviva (Jul 2022)
- Legal Name Innoviva, Inc.
Products & Services of La Jolla Pharmaceutical
La Jolla Pharmaceutical offers a comprehensive portfolio of products and services, including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
Treatment for critical care conditions in patients.
Therapy for infectious diseases caused by bacteria.
Treatment for drug-resistant microorganisms.
Investigational therapy for gonorrhea infections.
Funding Insights of La Jolla Pharmaceutical
- Total Rounds 3
- Last Round Debt – Conventional — $125M
- First Round $5.18M
(Apr 2011)
- Investors Count 1
All 3 funding rounds of La Jolla Pharmaceutical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $125M | Debt – Conventional | – | – | |
| Oct 2013 | $17.76M | Post-IPO | – | – | – |
| Apr 2011 | $5.18M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in La Jolla Pharmaceutical
La Jolla Pharmaceutical has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Innoviva and HealthCare Royalty Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare royalty investments are focused on US and UK markets. | – | healthcareroyalty.com | Stamford, United States | |
Respiratory prescription drugs are developed and in-licensed for COPD treatment. | 1996 | inva.com | Brisbane, United States |
Investor details for La Jolla Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of La Jolla Pharmaceutical
16 people are tracked at La Jolla Pharmaceutical (9 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 71.
| Name | Role | Group |
|---|---|---|
Larry Edwards | CEO | Leadership |
Marianne Zhen | Chief Accounting Officer | Leadership |
Pavel Raifeld | CEO | Leadership |
Marcie Cain | Chief People Officer | Leadership |
Steve Basso | Chief Financial Officer | Leadership |
Matt Ronsheim | President, IST | Leadership |
Austin Rory Hackett, M.D. | Vice President, Business Development | Leadership |
Narciso Pacis Jr. | Senior Director of Accounting and Finance | Leadership |
Christine Coyne | Chief Commercial Officer, IST | Leadership |
Odysseas Kostas | Chair | Board & advisors |
Jules Haimovitz | Director | Board & advisors |
Mark Dipaolo | Director | Board & advisors |
Sarah J. Schlesinger | Director | Board & advisors |
Deborah Birx | Independent Board Director, Chair Audit Committee | Board & advisors |
Sapna Srivastava | Director | Board & advisors |
Clarissa Lau | Senior General Accountant | Team |
Complete people profiles for La Jolla Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by La Jolla Pharmaceutical
La Jolla Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tetraphase Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Tetracycline analogs are developed for multidrug-resistant bacterial infections. | tphase.com | Watertown, United States | 2006 | Jun 2020 | $43M |
Complete acquisition details for La Jolla Pharmaceutical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of La Jolla Pharmaceutical
6 dated milestones of La Jolla Pharmaceutical across 33 years, from founding to its latest funding, stage changes and deals.
- Founded La Jolla Pharmaceutical is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $5.2M.
- Funding Latest funding round, Debt – Conventional, of $125.0M.
- Acquisition Acquires Tetraphase Pharmaceuticals.
- Exit Acquired by Innoviva.
Competitors of La Jolla Pharmaceutical
La Jolla Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| discmedicine.com | 2017 | Cambridge, United States | $140M | 23 | Developer of therapeutics for the treatment of hematologic diseases | |
| kerostx.com | 2016 | Lexington, United States | $90M | 136 | Small molecules are developed to treat hematologic and musculoskeletal disorders. | |
| jaspertx.com | 1999 | Redwood, United States | $84.1M | – | Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | |
| interiusbio.com | 2020 | Philadelphia, United States | $129.03M | 25 | Developer of gene therapies for treating multiple diseases | |
| spotlighttx.com | 2017 | Hayward, United States | $80.67M | 32 | Cancer therapeutics are developed using targeted gene editing platforms. | |
| veralox.com | 2017 | Frederick, United States | $47.47M | 6 | Small molecules are developed for thrombosis and diabetes treatments. | |
| renibus.com | 2013 | Southlake, United States | $153.52M | – | Therapeutics for kidney diseases are developed by Renibus Therapeutics. |
Detailed competitors of La Jolla Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of La Jolla Pharmaceutical
Websites that share an audience with La Jolla Pharmaceutical (lajollapharmaceutical.com).
Websites whose visitors overlap most with La Jolla Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
novimmune.com | novimmune.com | 100% | – | – | – |
| ptcbio.com | 100% | 24.4K | #1,154,739 | View details | |
| sandoz.com | 100% | 195.3K | #232,061 | View details | |
| bms.com | 60% | 809.8K | #67,210 | View details | |
ljpc.com | ljpc.com | 40% | – | – | – |
Latest news on La Jolla Pharmaceutical
Complete news archive for La Jolla Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to La Jolla Pharmaceutical
10 companies that operate in the same segment as La Jolla Pharmaceutical (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 | |
IVD for hemostasis characterization | 2004 | Charlottesville, Virginia, United States | USD 24.92 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about La Jolla Pharmaceutical
La Jolla Pharmaceutical was founded in 1989 and raised its 1st funding round 22 years after it was founded.
La Jolla Pharmaceutical is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Larry Edwards is the current CEO of La Jolla Pharmaceutical.
La Jolla Pharmaceutical has 71 employees.
Annual revenue of La Jolla Pharmaceutical is $75.72M as on Dec 31, 2021.
La Jolla Pharmaceutical is developing therapies for treating life-threatening diseases. The companys lead product candidate, LJPC-401 is its a formulation of synthetic human hepcidin (peptide hormones) for the potential treatment of hemochromatosis, and beta thalassemia. Its in phase II clinical trials. Other candidates of the company include LJPC-30Sa and LJPC-30Sb, are next-generation gentamicin derivatives for the treatment of bacterial infections and rare genetic disorders, LJPC-501 is its proprietary formulation of angiotensin II for treating catecholamine-resistant hypotension and hepatorenal syndrome.
La Jolla Pharmaceutical's top competitors include Keros Therapeutics, Disc Medicine and Freeline.
La Jolla Pharmaceutical offers GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
La Jolla Pharmaceutical has made 1 acquisition, including Tetraphase Pharmaceuticals.
La Jolla Pharmaceutical has 2 investors. Key investors include Innoviva, and HealthCare Royalty Partners.
La Jolla Pharmaceutical operates through Innoviva, Inc..
Yes. La Jolla Pharmaceutical was acquired by Innoviva in July 2022.